EUCTR2013-004622-29-DE进行中（未招募）1 期
A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 540
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria for MS Patients:
- •- Must have a documented diagnosis of relapsing MS (McDonald 2010 Criteria [Polman 2011]) at study screening.
- •- for subjects with a previous history treatment with BRACE-TA he/ she must have:
- •He/she must have been on therapy for at least 6 months (unless experiencing highly
- •active disease; see #6 below)
- •At least 9 T2-hyperintense lesions on a brain MRI scan, and
- •Experienced =1 relapse while on therapy within the last 6 months prior to study screening and either: * with =1 new T1-Gd+ lesion or =2 new T2 lesions on a brain MRI scan performed =6 months prior to study screening, or * =2 new T2 lesions on a brain MRI scan performed =6 months prior
- •to study screening,with comparison made to a T2 MRI scan performed up to 18 months before study screening.
- •- If the subject is DMT naïve at study screening, he/she must have experienced =2 disabling relapses in the 12 months prior to study screening. In addition, they must have had =1 new T1-Gd+ lesion or =2 new T2 lesions on a brain MRI scan performed =6 months prior to study screening, with comparison made to a T2 MRI scan performed up to 18 months prior to study screening.
- •- For subjects with highly active disease (defined by the criteria below), regardless of whether they are disease-modifying therapy (DMT)-naive or had previous exposure to BRACE TA, he/sge must have had:
- •=2 disabling relapses in the 12 months prior to study screening and
- •?* =1 new T1 Gd+ lesion on a brain MRI scan performed =6 months
- •prior to study screening
- •?* =2 new T2 lesions on a brain MRI scan performed =6 months prior to
- •study screening with comparison made to a T2
- •MRI scan performed up to 18 months before study screening
- •- Willing to take natalizumab or fingolimod as the only DMTs for the duration of the study treatment period.
- •- Must have an EDSS score from 0 to 5.5 inclusive at study screening.
- •Inclusion Criteria for Healthy Volunteers:
- •- Subjects who are generally healthy as demonstrated by physical examination and by medical history, with no history or evidence of major illnesses, diseases, or disorders.
- •- Subjects of childbearing potential must practice effective contraception and be willing and able to continue contraception for duration of the study.
- •- No History of drug or alcohol abuse (as defined by the Investigator) within 1 year prior to study screening.
- •- Willing and able to comply with scheduled visits and imaging services.
- •NOTE: Other protocol defined Inclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 540
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Excl Crit for MS Patients:
- •- Hist. of or pos. test result at study screening for HIV
- •- Hist. or pos. test result at study screening for HCV antibody or current hep B infect. (def. as positive for HBsAg and/or HBcAb). Subj with immunity to hepatitis B from either active
- •vaccination (defined as negative HBsAg, positive HBsAb and negative HBcAb) or from previous natural infection (defined as negative HBsAg, positive HBsAb immunoglobulin G, and positive HBcAb) are eligible to participate in the study
- •- Prior treatment with natalizumab or fingolimod
- •- Diagnosis of PPMS and/or SPMS
- •- Hist. of or known active malignant disease, including solid tumors and hematologic malignancies (subjects with cutaneous basal and squamous cell carcinoma that has been completely excised and considered cured prior to study screening remain eligible)
- •- History of opportunistic infections (including PML) or any clinically
- •significant cardiac, endocrinologic, hematologic, hepatic, immunologic,metabolic, urologic, pulmonary, neurologic (other than MS),dermatologic, psychiatric, and renal condition, or other major disease
- •- A clin. sig. infectious illness (e.g., pneumonia, septicemia) within the 1 month prior to study screening
- •- History of drug or alcohol abuse within 1 year prior to study screening
- •- Exposure to IVIg, monoclonal antibodies, cytokines, growth factors, soluble receptors, other recombinant products, or fusion proteins within 1 year prior to study screening
- •- Prior history of immunosuppressant use (e.g., mitoxantrone,
- •azathioprine, methotrexate, cyclophosphamide, mycophenolate,
- •cladribine, rituximab) in the last 12 months prior to study screening.Treatment with IV and/or oral corticosteroids (topical corticosteroids are acceptable) within 4 weeks of baseline DTI-MRI assessment
- •- An MS relapse that has occurred within the 30 days prior to
- •randomization and/or the subject has not stabilized from a previous relapse prior to randomization
- •- Current/previous particip. in investigational drug studies within 90 days prior to study screening or 5 times the compound's half-life, whichever is longer
- •- Subject has any contraindications to fingolimod or natalizumab, as described in the respective Prescribing Information or has any medical condition as described in the warnings and precautions of the respective Prescribing Information that makes the subject unsuitable for participation in the study
- •- Subject treated with teriflunomide who did not undergo an accelerated elimination procedure prior to study screening.
- •- Hist. or evidence of macular edema on ophthalmologic exam
- •- Hist. of congenital QT prolongation, unexplained hypokalemia,
- •myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure in last 6 months
- •- Mobitz type II second degree or third degree AV block or sick sinus syndrome, symptomatic bradycardia, recurrent syncope, or severe untreated sleep apnea
- •- Baseline corrected QTc (Fridericia [QTcF] or Bazett's [QTcB] formula) interval =470 ms in females and =450 ms in males
- •- Treat. with Class Ia (e.g., procainamide, quinidine, ajmaline,
- •disopyramide) or Class III (amiodarone, bretylium, dofelitide, sotalol, ibulitide, azilimide) anti-arrhythmic drugs
- •- Concurrent therapy with drugs that slow heart rate (e.g., betablockers,heart-rate lowering calcium channel blockers such as
- •diltiazem, verapamil or digoxin), prolong the QTc interval, or are potent inducers of CYP450
- •- Hypertens. not controlled with prescribed
研究者
相似试验
进行中（未招募）
不适用
Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) SubjectsMultiple Sclerosis (MS)MedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-004622-29-ITBiogen Idec Research Limited540
进行中（未招募）
1 期
Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) SubjectsMultiple Sclerosis (MS)MedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-004622-29-ESBiogen Idec Research Limited540
进行中（未招募）
1 期
Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) SubjectsMultiple Sclerosis (MS)MedDRA version: 19.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-004622-29-DKBiogen Idec Research Limited540
进行中（未招募）
1 期
Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) SubjectsEUCTR2013-004622-29-GBBiogen Idec Research Limited540
进行中（未招募）
1 期
Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) SubjectsEUCTR2013-004622-29-CZBiogen Idec Research Limited540